cimetidine has been researched along with Malignant Melanoma in 38 studies
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifteen evaluable patients with metastatic malignant melanoma who had received no prior chemotherapy were treated with high-dose cimetidine orally, 600 mg q." | 9.07 | Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial. ( Einhorn, LH; Mandanas, R; Schultz, S; Scullin, D, 1991) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Human melanoma cells were treated in culture with the histamine (H2) agonist S-(3-(N-N-dimethylamino)propyl)isothiourea (dimaprit), a partial agonist, S-(2-(N,N-dimethylamino)ethyl)-isothiourea (nordimaprit), and two analogues of nordimaprit, S-(2-(N,N-diethylamino)ethyl)isothiourea (DENOR) and S-(2-(N,N-diisopropylamino)ethyl)isothiourea (DINOR), to investigate the effects on toxicity and tyrosinase activity." | 7.68 | Antiproliferative and depigmenting effects of the histamine (H2) agonist dimaprit and its derivatives on human melanoma cells. ( Fechner, GA; Jacobs, JJ; McEwan, MT; Parsons, PG; Takahashi, H, 1992) |
| "Sixty-two patients with biopsy-proven, measurable disseminated malignant melanoma received either the combination IFN-alpha 2A with BCNU (30 patients) or the combination cimetidine with BCNU (32 patients) in parallel noncomparative Phase II trials." | 7.68 | Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma. ( Creagan, ET; Kardinal, CG; McCormack, GW; McHale, MS; Morton, RF; Schaid, DJ; Wiesenfeld, M, 1991) |
| "Cimetidine, an H2 histamine antagonist, was used in the clinical management of progressive, multifocal melanomatosis in 3 adult gray horses." | 7.68 | Cimetidine for treatment of melanomas in three horses. ( Goetz, TE; Johnson, PJ; Keegan, KG; Ogilvie, GK, 1990) |
| "Based on previous results demonstrating that coumarin and cimetidine render objective tumor regressions in renal cell carcinoma, we conducted a pilot study to determine whether these drugs possess activity against malignant melanoma." | 7.67 | Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study. ( Butler, K; Cantrell, J; Marshall, ME; Mendelsohn, L; Wiseman, C, 1989) |
| "Histamine induced a concentration-dependent increase in intracellular cyclic-AMP of the two human melanoma cell lines SK23 and DX3." | 7.67 | Demonstration of histamine H2 receptors on human melanoma cells. ( Evanson, JM; Hart, IR; Taylor, DJ; Whitehead, RJ; Woolley, DE, 1988) |
| "The effect of cimetidine, an H-2 receptor antagonist, on activation of PBL from both normal individuals and melanoma patients was studied." | 7.67 | The effect of cimetidine on PBL from healthy donors and melanoma patients: augmentation of T cell responses to TCGF mitogens and alloantigens and of TCGF production. ( Adler, A; Eisenthal, A; Monselise, J; Zinger, R, 1986) |
| "Following recent reports suggesting that the addition of cimetidine to interferon may enhance response rates in patients with metastatic malignant melanoma, we have completed a Phase II study of the use of recombinant alpha 2 interferon and cimetidine in patients with advanced malignant melanoma and who had progressive disease following interferon therapy alone." | 7.67 | Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma. ( Mughal, TI; Robinson, WA; Spiegel, R; Thomas, MR, 1988) |
| "In vitro synergism between interferons (IFNs) and chemotherapeutic drugs has been demonstrated, and an enhancement of IFN's antiproliferative effects when combined with cimetidine has been suggested in melanoma patients." | 7.67 | Combination of fibroblast interferon (HuIFN beta), carboxamide (DTIC), and cimetidine for advanced malignant melanoma. ( Abdi, EA; McPherson, TA; Tan, YH, 1986) |
| "Immunostimulant therapy with coumarin and cimetidine was evaluated in 17 patients with advanced malignant melanoma." | 7.67 | Combined treatment of advanced malignant melanoma with coumarin and cimetidine. A phase II study. ( Langvad, E; Pedersen, L; Rose, C, 1987) |
| "Thirty-five eligible patients with disseminated malignant melanoma received intramuscular recombinant leukocyte interferon (IFN-rA), 50 X 10(6) U/m2 three times weekly (TIW) for an intended duration of 12 weeks concomitant with daily oral cimetidine, 1,200 mg/d in four divided doses." | 7.67 | Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. ( Ahmann, DL; Creagan, ET; Frytak, S; Green, SJ; Itri, LM; Long, HJ, 1985) |
| "With the aim of potentiating the anti-tumour effect of interferon in metastatic malignant melanoma by concomitant inhibition of suppressor T cells, oral cimetidine (histamine-2 receptor antagonist) medication was added to interferon (HuIFN-alpha(Le] therapy in a series of 20 patients." | 7.66 | Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine. ( Borgström, S; Flodgren, P; Jönsson, PE; Lindström, C; Sjögren, HO, 1983) |
| "Histamine treatment accelerated tumor growth, but only in normal animals and had little effect on tumor growth in immunocompromised hosts." | 5.27 | The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. ( Askenase, PW; Nordlund, JJ, 1983) |
| "Fifteen evaluable patients with metastatic malignant melanoma who had received no prior chemotherapy were treated with high-dose cimetidine orally, 600 mg q." | 5.07 | Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial. ( Einhorn, LH; Mandanas, R; Schultz, S; Scullin, D, 1991) |
| "Ninety-six patients with advanced malignant melanoma received thrice weekly im recombinant leukocyte A interferon (Roferon-A) in three consecutive phase II trials utilizing doses of 12 X 10(6) U/m2, 50 X 10(6) U/m2, and 50 X 10(6) U/m2 plus cimetidine." | 5.06 | Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. ( Ahmann, DL; Chang, MN; Creagan, ET; Frytak, S; Itri, LM; Long, HJ, 1986) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Human melanoma cells were treated in culture with the histamine (H2) agonist S-(3-(N-N-dimethylamino)propyl)isothiourea (dimaprit), a partial agonist, S-(2-(N,N-dimethylamino)ethyl)-isothiourea (nordimaprit), and two analogues of nordimaprit, S-(2-(N,N-diethylamino)ethyl)isothiourea (DENOR) and S-(2-(N,N-diisopropylamino)ethyl)isothiourea (DINOR), to investigate the effects on toxicity and tyrosinase activity." | 3.68 | Antiproliferative and depigmenting effects of the histamine (H2) agonist dimaprit and its derivatives on human melanoma cells. ( Fechner, GA; Jacobs, JJ; McEwan, MT; Parsons, PG; Takahashi, H, 1992) |
| "B16-C3 murine melanoma, A375P human melanotic melanoma, and C32 human amelanotic melanoma cells were incubated in the presence of (0-4 mM) H2-antagonists, ranitidine and cimetidine." | 3.68 | The effects of histamine H2 receptor antagonists on melanogenesis and cellular proliferation in melanoma cells in culture. ( Uçar, K, 1991) |
| "Sixty-two patients with biopsy-proven, measurable disseminated malignant melanoma received either the combination IFN-alpha 2A with BCNU (30 patients) or the combination cimetidine with BCNU (32 patients) in parallel noncomparative Phase II trials." | 3.68 | Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma. ( Creagan, ET; Kardinal, CG; McCormack, GW; McHale, MS; Morton, RF; Schaid, DJ; Wiesenfeld, M, 1991) |
| "Cimetidine, an H2 histamine antagonist, was used in the clinical management of progressive, multifocal melanomatosis in 3 adult gray horses." | 3.68 | Cimetidine for treatment of melanomas in three horses. ( Goetz, TE; Johnson, PJ; Keegan, KG; Ogilvie, GK, 1990) |
| "Based on previous results demonstrating that coumarin and cimetidine render objective tumor regressions in renal cell carcinoma, we conducted a pilot study to determine whether these drugs possess activity against malignant melanoma." | 3.67 | Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study. ( Butler, K; Cantrell, J; Marshall, ME; Mendelsohn, L; Wiseman, C, 1989) |
| "Histamine induced a concentration-dependent increase in intracellular cyclic-AMP of the two human melanoma cell lines SK23 and DX3." | 3.67 | Demonstration of histamine H2 receptors on human melanoma cells. ( Evanson, JM; Hart, IR; Taylor, DJ; Whitehead, RJ; Woolley, DE, 1988) |
| "The effect of cimetidine, an H-2 receptor antagonist, on activation of PBL from both normal individuals and melanoma patients was studied." | 3.67 | The effect of cimetidine on PBL from healthy donors and melanoma patients: augmentation of T cell responses to TCGF mitogens and alloantigens and of TCGF production. ( Adler, A; Eisenthal, A; Monselise, J; Zinger, R, 1986) |
| "In vitro synergism between interferons (IFNs) and chemotherapeutic drugs has been demonstrated, and an enhancement of IFN's antiproliferative effects when combined with cimetidine has been suggested in melanoma patients." | 3.67 | Combination of fibroblast interferon (HuIFN beta), carboxamide (DTIC), and cimetidine for advanced malignant melanoma. ( Abdi, EA; McPherson, TA; Tan, YH, 1986) |
| "Immunostimulant therapy with coumarin and cimetidine was evaluated in 17 patients with advanced malignant melanoma." | 3.67 | Combined treatment of advanced malignant melanoma with coumarin and cimetidine. A phase II study. ( Langvad, E; Pedersen, L; Rose, C, 1987) |
| "The histamine-2 receptor antagonist cimetidine (10(-5)M) and the prostaglandin synthesis inhibitor indomethacin (10(-8)M) augmented natural killer cell activity in the majority of healthy controls and patients with advanced melanoma and in a lower frequency of patients with colorectal carcinoma." | 3.67 | Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. ( Flodgren, P; Sjögren, HO, 1985) |
| "With the aim of potentiating the anti-tumour effect of interferon in metastatic malignant melanoma by concomitant inhibition of suppressor T cells, oral cimetidine (histamine-2 receptor antagonist) medication was added to interferon (HuIFN-alpha(Le] therapy in a series of 20 patients." | 3.66 | Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine. ( Borgström, S; Flodgren, P; Jönsson, PE; Lindström, C; Sjögren, HO, 1983) |
| "Histamine treatment accelerated tumor growth, but only in normal animals and had little effect on tumor growth in immunocompromised hosts." | 1.27 | The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. ( Askenase, PW; Nordlund, JJ, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (65.79) | 18.7374 |
| 1990's | 10 (26.32) | 18.2507 |
| 2000's | 3 (7.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Szincsák, N | 2 |
| Hegyesi, H | 2 |
| Hunyadi, J | 2 |
| Martin, G | 1 |
| Lázár-Molnár, E | 1 |
| Kovács, P | 1 |
| Rivera, E | 1 |
| Falus, A | 2 |
| Juhász, I | 2 |
| Thornes, RD | 2 |
| Lynch, G | 2 |
| Sheehan, MV | 2 |
| Creagan, ET | 6 |
| Ahmann, DL | 4 |
| Green, SJ | 2 |
| Long, HJ | 4 |
| Rubin, J | 1 |
| Schutt, AJ | 1 |
| Dziewanowski, ZE | 1 |
| Flodgren, P | 3 |
| Borgström, S | 2 |
| Jönsson, PE | 1 |
| Lindström, C | 1 |
| Sjögren, HO | 3 |
| Hill, NO | 1 |
| Pardue, A | 1 |
| Khan, A | 1 |
| Hill, RW | 1 |
| Aleman, C | 1 |
| Hilario, R | 1 |
| Hill, JM | 1 |
| Osther, K | 1 |
| Nordlund, JJ | 1 |
| Askenase, PW | 1 |
| von Eyben, FE | 1 |
| Axelsson, B | 1 |
| Adler, A | 2 |
| Schachter, J | 1 |
| Barenholz, Y | 1 |
| Bar, LK | 1 |
| Klein, T | 1 |
| Korytnaya, R | 1 |
| Sulkes, A | 1 |
| Michowiz, R | 1 |
| Cohen, Y | 1 |
| Kedar, I | 2 |
| Hellstrand, K | 1 |
| Hermodsson, S | 1 |
| Naredi, P | 1 |
| Mellqvist, UH | 1 |
| Brune, M | 1 |
| Piura, B | 1 |
| Meirovitz, M | 1 |
| Schmidt, H | 1 |
| Geertsen, PF | 1 |
| Fode, K | 1 |
| Rytter, C | 1 |
| Bastholt, L | 1 |
| von der Maase, H | 1 |
| Frytak, S | 3 |
| Chang, MN | 2 |
| Itri, LM | 3 |
| Bajorin, DF | 1 |
| Chapman, PB | 1 |
| Wong, GY | 1 |
| Cody, BV | 1 |
| Cordon-Cardo, C | 1 |
| Dantes, L | 1 |
| Templeton, MA | 1 |
| Scheinberg, D | 1 |
| Oettgen, HF | 1 |
| Houghton, AN | 1 |
| Fechner, GA | 1 |
| Parsons, PG | 1 |
| McEwan, MT | 1 |
| Jacobs, JJ | 1 |
| Takahashi, H | 1 |
| Uçar, K | 1 |
| Mandanas, R | 1 |
| Schultz, S | 1 |
| Scullin, D | 1 |
| Einhorn, LH | 1 |
| Weiss, RB | 1 |
| Donehower, RC | 1 |
| Wiernik, PH | 2 |
| Ohnuma, T | 1 |
| Gralla, RJ | 1 |
| Trump, DL | 1 |
| Baker, JR | 1 |
| Van Echo, DA | 1 |
| Von Hoff, DD | 1 |
| Leyland-Jones, B | 1 |
| Morton, RF | 2 |
| Schaid, DJ | 1 |
| Kardinal, CG | 1 |
| McCormack, GW | 1 |
| McHale, MS | 1 |
| Wiesenfeld, M | 1 |
| Goetz, TE | 1 |
| Ogilvie, GK | 1 |
| Keegan, KG | 1 |
| Johnson, PJ | 1 |
| Harland, CC | 1 |
| Saihan, EM | 1 |
| Marshall, ME | 1 |
| Butler, K | 1 |
| Cantrell, J | 1 |
| Wiseman, C | 1 |
| Mendelsohn, L | 1 |
| Timm, EG | 1 |
| Rozek, SL | 1 |
| Whitehead, RJ | 1 |
| Taylor, DJ | 1 |
| Evanson, JM | 1 |
| Hart, IR | 1 |
| Woolley, DE | 1 |
| Schwartz, EL | 1 |
| Einzig, A | 1 |
| Strauman, JJ | 1 |
| Lipton, RB | 1 |
| Dutcher, JP | 1 |
| Eisenthal, A | 1 |
| Monselise, J | 1 |
| Zinger, R | 1 |
| Steiner, A | 2 |
| Wolf, C | 1 |
| Pehamberger, H | 2 |
| McLeod, GR | 1 |
| Mughal, TI | 1 |
| Robinson, WA | 1 |
| Thomas, MR | 1 |
| Spiegel, R | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
| Abdi, EA | 1 |
| McPherson, TA | 1 |
| Tan, YH | 1 |
| Pedersen, L | 1 |
| Rose, C | 1 |
| Langvad, E | 1 |
| Wolff, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel[NCT04237090] | Phase 3 | 27 participants (Actual) | Interventional | 2020-02-14 | Completed | ||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for cimetidine and Malignant Melanoma
| Article | Year |
|---|---|
Histamine and cytokine therapy.
Topics: Animals; Antineoplastic Agents; Cimetidine; Combined Modality Therapy; Histamine; Humans; Immunother | 1998 |
6 trials available for cimetidine and Malignant Melanoma
| Article | Year |
|---|---|
Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects.
Topics: Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Cimetidine; Combined Modality Therapy; Cytotoxic | 1995 |
Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2000 |
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
Topics: Adjuvants, Immunologic; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 1987 |
Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cimetidine; Drug Administration Schedule; Drug | 1991 |
Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Clinical Trials as Topic; DNA, Recombina | 1986 |
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
31 other studies available for cimetidine and Malignant Melanoma
| Article | Year |
|---|---|
Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Cell Division; Cim | 2002 |
Different h2 receptor antihistamines dissimilarly retard the growth of xenografted human melanoma cells in immunodeficient mice.
Topics: Aged; Animals; Benzhydryl Compounds; Cell Division; Cimetidine; Ethylamines; Histamine H2 Antagonist | 2002 |
Cimetidine and coumarin therapy of melanoma.
Topics: Adult; Aged; Cimetidine; Coumarins; Drug Antagonism; Drug Therapy, Combination; Female; Guanidines; | 1982 |
Combination of cimetidine with other drugs for treatment of cancer.
Topics: Aged; Animals; Cimetidine; Coumarins; Female; Guanidines; Histamine; Humans; Interferons; Male; Mela | 1983 |
Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma.
Topics: Adult; Aged; Cimetidine; Drug Evaluation; Female; Humans; Interferon Type I; Male; Melanoma; Middle | 1984 |
Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine.
Topics: Adult; Aged; Cimetidine; Combined Modality Therapy; Female; Humans; Interferon Type I; Lung Neoplasm | 1983 |
Coumarin and cimetidine in malignant melanoma.
Topics: Adult; Aged; Cimetidine; Coumarins; Female; Guanidines; Humans; Male; Melanoma; Middle Aged | 1983 |
Interferon and cimetidine for malignant melanoma.
Topics: Cimetidine; Guanidines; Humans; Interferon Type I; Melanoma | 1983 |
The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice.
Topics: Animals; Chromones; Cimetidine; Histamine; Histamine Antagonists; Immunosuppression Therapy; Male; M | 1983 |
Human leukocyte interferon and cimetidine for metastatic melanoma.
Topics: Adult; Aged; Cimetidine; Drug Therapy, Combination; Female; Guanidines; Humans; Interferon Type I; M | 1982 |
Long-term disease-free survival following surgery and active specific immunotherapy with allogeneic vaccine in a patient with high-risk malignant melanoma of the vulva.
Topics: Adult; Cancer Vaccines; Cimetidine; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Sti | 1998 |
Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.
Topics: Adult; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antigens, CD; Cimetidine; Comple | 1992 |
Antiproliferative and depigmenting effects of the histamine (H2) agonist dimaprit and its derivatives on human melanoma cells.
Topics: Cell Division; Cell Survival; Cimetidine; Dimaprit; Humans; Immunoblotting; Melanoma; Microscopy, El | 1992 |
The effects of histamine H2 receptor antagonists on melanogenesis and cellular proliferation in melanoma cells in culture.
Topics: Animals; Cell Division; Cell Line; Cimetidine; Dose-Response Relationship, Drug; Humans; Kinetics; M | 1991 |
Hypersensitivity reactions from taxol.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Colonic Neoplasms; Dexamethas | 1990 |
Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cimetidine; Drug Evaluation | 1991 |
Cimetidine for treatment of melanomas in three horses.
Topics: Animals; Cimetidine; Horse Diseases; Horses; Male; Melanoma; Skin Neoplasms | 1990 |
Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine.
Topics: Administration, Oral; Administration, Topical; Aged; Cimetidine; Cyclopropanes; Drug Administration | 1989 |
Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Coumarin | 1989 |
Cimetidine in malignant melanoma.
Topics: Adjuvants, Immunologic; Cimetidine; Humans; Immunity, Cellular; Killer Cells, Natural; Melanoma; T-L | 1989 |
Demonstration of histamine H2 receptors on human melanoma cells.
Topics: Adenylyl Cyclases; Cimetidine; Cyclic AMP; Dose-Response Relationship, Drug; Histamine; Humans; Mela | 1988 |
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Admin | 1987 |
The effect of cimetidine on PBL from healthy donors and melanoma patients: augmentation of T cell responses to TCGF mitogens and alloantigens and of TCGF production.
Topics: Cells, Cultured; Cimetidine; Humans; Interleukin-2; Lymphocyte Activation; Lymphocyte Culture Test, | 1986 |
Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma.
Topics: Cimetidine; Drug Evaluation; Drug Therapy, Combination; Fatigue; Female; Fever; Humans; Interferon T | 1987 |
Alpha-interferons in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Dacarbazine; Humans; Interferon Type I; | 1988 |
Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Female; Interferon Type I; Male; Melanom | 1988 |
Combination of fibroblast interferon (HuIFN beta), carboxamide (DTIC), and cimetidine for advanced malignant melanoma.
Topics: Adult; Cimetidine; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon | 1986 |
Combined treatment of advanced malignant melanoma with coumarin and cimetidine. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Coumarins; Drug Evaluation; | 1987 |
Recombinant leukocyte A interferon and cimetidine treatment in disseminated melanoma.
Topics: Adult; Aged; Cimetidine; Drug Therapy, Combination; Female; Humans; Interferon Type I; Male; Melanom | 1986 |
Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon.
Topics: Antibody-Dependent Cell Cytotoxicity; Carcinoma; Cimetidine; Colonic Neoplasms; Cytotoxicity, Immuno | 1985 |
Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma.
Topics: Administration, Oral; Cimetidine; Combined Modality Therapy; Drug Evaluation; Female; Humans; Inject | 1985 |